GE-38 IDENTIFYING THE TREATMENT-RESISTANT MESENCHYMAL SIGNATURE BY COMPARATIVE ANALYSES BETWEEN GLIOMA SPHERE-FORMING CELLS AND THEIR GLIOBLASTOMAS OF ORIGIN

The mesenchymal (Mes) subtype of glioblastoma (MesGBM) correlates with poor patient prognosis. Surprisingly, agents that target mesenchymal tumors, such as the antiangiogenesis drug bevacizumab, failed to show a benefit in MesGBM. The expression of MesGBM might result from both cells from the surrou...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Wang, Qianghu, Ezhilarasan, Ravesanker, Zheng, Siyuan, Gumin, Joy, Heffernan, Tim, Draetta, Giulio, Lang, Frederick, Verhaak, Roeland, Sulman, Erik
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2014
Sujets:
Abstracts
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218203/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou256.37
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires